Search / Trial NCT00000167

Complications of Age-Related Macular Degeneration Prevention Trial

Launched by NATIONAL EYE INSTITUTE (NEI) · Sep 23, 1999

Apply for Trial

Trial Information

Current as of July 23, 2024

Completed

Keywords

Age Related Macular Degeneration

Description

Complications of age-related macular degeneration (AMD) are the leading cause of severe vision loss among people aged 65 and over in the United States and many Western countries. Most, (approximately 90 percent), of this vision loss is due to the neovascular (or wet) form of AMD. The word neovascular describes the development of new, abnormal blood vessels in the back of the eye. Unfortunately, the majority of these new vessels are not amenable to currently available treatments. The first sign that an eye may develop AMD is the presence of drusen, yellowish deposits under the retina. Curre...

Gender

All

Eligibility criteria

  • Patients eligible for CAPT can be either male or female and meet the following criteria:
  • Age at least 50 years old
  • Vision in each eye must measure 20/40 or better.
  • At least 10 large drusen in each eye
  • Available for follow-up examinations for 5 years after enrollment
  • Final eligibility is determined through a detailed eye examination by a CAPT-certified ophthalmologist.

Attachments

readout_NCT00000167_2024-07-23.pdf

4.5 MB

NCT00000167_study_protocol.pdf

4.5 MB

About company

The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Contacts

JC

Jennifer Cobb

Immunology at National Institute of Allergy and Infectious Diseases (NIAID)

Locations

Rochester, Minnesota, United States

Atlanta, Georgia, United States

Iowa City, Iowa, United States

Mesa, Arizona, United States

Peoria, Arizona, United States

San Francisco, California, United States

Tampa, Florida, United States

Chicago, Illinois, United States

Harvey, Illinois, United States

Louisville, Kentucky, United States

Baltimore, Maryland, United States

Boston, Massachusetts, United States

Royal Oak, Michigan, United States

St. Louis, Missouri, United States

Edison, New Jersey, United States

Lakewood, New Jersey, United States

Charlotte, North Carolina, United States

Cleveland, Ohio, United States

Columbus, Ohio, United States

Portland, Oregon, United States

Portland, Oregon, United States

Philadelphia, Pennsylvania, United States

Dallas, Texas, United States

Madison, Wisconsin, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

5 years

Reviews (48)

4.6

All reviews come from applied patients

5 stars
41
4 stars
6
3 stars
2
2 stars
0
1 stars
0
Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Michael Foster
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Dries Vincent
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Discussion 0